https://dxm-atlas.org/en/interactions/linezolid/
CompareKey points for this combination
Weak, reversible inhibition of monoamine oxidase (MAO), an enzyme that breaks down monoamines. The review reports negative findings from controlled DXM testing at therapeutic exposure. These findings apply to the tested conditions. Concern under other conditions comes from the mechanism. AUVELITY labeling contraindicates use together [2, 39, 40].
General concepts in this text
Enzyme
A protein that helps chemical transformations in cells.
A transformation can build or break down a substance.
Sources: Enzyme
- OpenStax: General Neurochemistry Principles · Introduction to Behavioral Neuroscience, published 2024-11-13
MAO — monoamine oxidase
An enzyme involved in breaking down serotonin.
Breakdown and reuptake are different processes.
Sources: MAO — monoamine oxidase
- OpenStax: Neurotransmitters Made from Amino Acids · Introduction to Behavioral Neuroscience, published 2024-11-13
Monoamines
A group of substances formed in living organisms; several act as chemical messengers between nerve cells.
Examples include serotonin, dopamine and norepinephrine.
Sources: Monoamines
- NLM MeSH: Biogenic Monoamines (D015306) · Live MeSH entry read 2026-10-13; year introduced 1989; no separate visible revision date
- OpenStax Anatomy and Physiology 2e, 12.5 Communication Between Neurons · Second edition; online section read 2026-10-13
How well is this understood?
Mechanism confidence: high
Confidence in the mechanism: high
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: medium
Confidence in direct human evidence involving DXM: medium
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodHow do the substances interact?
How can the effects add up?
ⓘ
MAO — monoamine oxidase
An enzyme involved in breaking down serotonin.
Breakdown and reuptake are different processes.
Sources: MAO — monoamine oxidase
- OpenStax: Neurotransmitters Made from Amino Acids · Introduction to Behavioral Neuroscience, published 2024-11-13
- Hendershot and colleagues’ controlled healthy-volunteer study found no significant blood-pressure effect with DXM and only a small decrease in DXO concentrations. Finding below: Finding [39]
- Current linezolid labeling also reports no observed serotonin-syndrome signs in the studied DXM combination [39, 40].
Label findings below:
Serotonin toxicity
A condition caused by excessive serotonin activity in the nervous system.
Also called serotonin syndrome. Features can include tremor and involuntary muscle jerks, raised body temperature, a fast heartbeat, agitation or confusion.
Sources: Serotonin toxicity
- Ables and Nagubilli: Prevention, Diagnosis, and Management of Serotonin Syndrome · American Family Physician 81(9), 1139–1142 (2010)
- Chiew and Isbister: Management of serotonin syndrome (toxicity) · British Journal of Clinical Pharmacology 91(3), 654–661 (2025); first published 26 June 2024; DOI 10.1111/bcp.16152
What remains unknown?
These are negative results for the measures studied at therapeutic exposures. Their scope is limited to the study conditions.
Sources
Check the review’s wording
- [2] AUVELITY prescribing information · Open publication
- [39] Linezolid: pharmacokinetic and pharmacodynamic evaluation of coadministration with pseudoephedrine HCl, phenylpropanolamine HCl, and dextromethorpan HBr · Open publication
- [40] LINEZOLID prescribing information · Open publication
Evidence and sources
Research publication
[39] · Linezolid: pharmacokinetic and pharmacodynamic evaluation of coadministration with pseudoephedrine HCl, phenylpropanolamine HCl, and dextromethorpan HBr · 2001
Finding [39]
- What was found?
Hendershot and colleagues’ controlled healthy-volunteer study found no significant blood-pressure effect with DXM and only a small decrease in DXO concentrations.
- What limits this finding?
These are negative results for the measures studied at therapeutic exposures. Their scope is limited to the study conditions.
Prescribing information
[40] · LINEZOLID prescribing information
Finding [40]
- What does the label say?
- What does this label information cover?
These are negative results for the measures studied at therapeutic exposures. Their scope is limited to the study conditions.